GenomeQuest and Ingenuity Systems Partner in Next-Generation Sequencing and Personalized Medicine Research

The integration of IPA from Ingenuity Systems and SDM from GenomeQuest provides researchers with the opportunity to better understand NGS experimental results placing them into known and predicted biological contexts. Personalized medicine researchers are now able to identify and validate targets for stratification, and then narrow down these targets or generate new hypotheses.

GenomeQuest and Ingenuity Systems today announced a partnership to support next-generation sequencing (NGS) workflows specifically targeted for personalized medicine research. The companies will integrate GenomeQuest’s Sequence Data Management (SDM) platform with Ingenuity’s IPA software.  As a result, researchers can seamlessly exchange gene information, perform interactive analysis, and create and test hypotheses across the domains of genome sequencing and biological pathways.

“Biological context is absolutely critical to deriving insights from NGS datasets.  This partnership removes a major data analysis hurdle for our common customers in personalized medicine research,” states Doug Bassett, Ph.D, Chief Scientific Officer and Chief Technology Officer.  “By integrating SDM and IPA, researchers can take NGS experimental results and place them into known and predicted biological contexts that include biological processes, functions, diseases, pathways, compounds, and relationships. This creates a fast and efficient way for researchers to move from a list of genes, isoforms, or variants to high-value discovery outcomes like identifying novel disease-causing variants, prioritizing drug targets, and generating testable hypotheses.”

Richard Resnick, GenomeQuest CEO comments, “The name of the game in personalized medicine research is to identify and validate targets for stratification.  With this integration, researchers can use multi-genome analysis and comparative datasets to enrich and contract their data to the most promising targets and then, armed with pathways analysis and biological process tools, validate and narrow these targets or generate new hypotheses.  Researchers can have high confidence in these contextual studies because they are leveraging the manually reviewed biological findings that Ingenuity curates from the peer-reviewed literature.”

The integration of SDM and IPA will be available in the GenomeQuest RNA-Seq and multi-genome analysis workflows.  The integration is built on the respective application platforms: the GenomeQuest three-level API which provides complete access to all functionality and data at the sequence engine, workflow, and user presentation levels; and the IPA Integration Module which provides direct links to all content and analysis capabilities within IPA.

More About GenomeQuest
GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The core technology of the company is the GQ-Engine — a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale. Visit genomequest.com for more information.

About Ingenuity® Systems
Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com

Click here to go to the Ingenuity.com home page.